Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saul J Priceman

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Cancer Treatment and Research|June 19, 2019
Precision Medicine-Enabled Cancer ImmunotherapyJohn K Lee, Saul J Priceman
Molecular Therapy Oncolytics|June 13, 2022
Advancing together and moving forward: Combination gene and cellular immunotherapiesSaul J Priceman, Waseem Cheema, Prasad S Adusumilli
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 24, 2025
An IL-12 renaissance: Engineering tumor-restricted IL-12 to improve solid tumor T cell therapiesJun Ishihara, John K Lee, Saul J Priceman
Cancer Treatment and Research|March 28, 2020
CAR T Cell Therapy Progress and Challenges for Solid TumorsLawrence A Stern, Vanessa D Jonsson, Saul J Priceman
Current Opinion in Oncology|September 10, 2015
Smart CARs engineered for cancer immunotherapySaul J Priceman, Stephen J Forman, Christine E Brown
Cell Reports|March 18, 2014
S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3Saul J Priceman, Shudan Shen, Lin Wang, et al.
Cancer Immunology Research|May 31, 2015
STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 AxisChanyu Yue, Shudan Shen, Jiehui Deng, et al.
Breast Cancer Research : BCR|May 15, 2025
CD105<sup>+</sup> fibroblasts support an immunosuppressive niche in women at high risk of breast cancer initiationEric G Carlson, Jennifer C Lopez, Yukiko Yamaguchi, et al.
Med (New York, N.Y.)|February 17, 2026
Current state of CAR-T cell therapies for solid tumorsReginaldo Rosa, Jiangyue Liu, Cathy Lu, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 21, 2009
Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null miceAjay J Narasimha, Junji Watanabe, Tomo-o Ishikawa, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Cancer Treatment and Research|June 19, 2019
Precision Medicine-Enabled Cancer ImmunotherapyJohn K Lee, Saul J Priceman
Molecular Therapy Oncolytics|June 13, 2022
Advancing together and moving forward: Combination gene and cellular immunotherapiesSaul J Priceman, Waseem Cheema, Prasad S Adusumilli
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 24, 2025
An IL-12 renaissance: Engineering tumor-restricted IL-12 to improve solid tumor T cell therapiesJun Ishihara, John K Lee, Saul J Priceman
Cancer Treatment and Research|March 28, 2020
CAR T Cell Therapy Progress and Challenges for Solid TumorsLawrence A Stern, Vanessa D Jonsson, Saul J Priceman
Current Opinion in Oncology|September 10, 2015
Smart CARs engineered for cancer immunotherapySaul J Priceman, Stephen J Forman, Christine E Brown
Cell Reports|March 18, 2014
S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3Saul J Priceman, Shudan Shen, Lin Wang, et al.
Cancer Immunology Research|May 31, 2015
STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 AxisChanyu Yue, Shudan Shen, Jiehui Deng, et al.
Breast Cancer Research : BCR|May 15, 2025
CD105<sup>+</sup> fibroblasts support an immunosuppressive niche in women at high risk of breast cancer initiationEric G Carlson, Jennifer C Lopez, Yukiko Yamaguchi, et al.
Med (New York, N.Y.)|February 17, 2026
Current state of CAR-T cell therapies for solid tumorsReginaldo Rosa, Jiangyue Liu, Cathy Lu, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 21, 2009
Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null miceAjay J Narasimha, Junji Watanabe, Tomo-o Ishikawa, et al.
Pageof 7